कंपनी का अवलोकन
Erasca, Inc. is a clinical-stage precision oncology enterprise dedicated to the discovery, development, and commercialization of novel therapies designed specifically for patients suffering from cancers driven by the RAS/MAPK pathway. This biotechnology firm operates within the broader healthcare sector, with its specific industry focus placed on biotechnology, a domain characterized by high research costs and significant regulatory hurdles before product approval. The company's total market capitalization stands at $5.40B, employing a workforce of 103 individuals to execute its scientific and commercial objectives. Although the annual revenue is listed as N/A in current reporting, the substantial market cap of $5.40B indicates that the market places a high premium on the company's future potential rather than its immediate earnings, suggesting investors are betting heavily on the success of its product pipeline, particularly ERAS-0015, which targets RAS-mutated solid tumors.
वित्तीय स्वास्थ्य
The company reports a Net Income (TTM) of $-124,546,000 and an EBITDA of $-128,298,000, while Revenue (TTM) is N/A, revealing a cost structure where operational expenses significantly outweigh current top-line generation. The gap between the negligible revenue and the substantial net loss indicates that the firm is currently in a heavy investment phase, burning cash to fund clinical trials and research activities before achieving profitability. Free Cash Flow stands at $-66,761,124, which implies a constrained financial flexibility where the company must rely on external capital markets or existing reserves to fund its operations without generating internal cash flow. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure typical for biotechnology companies in the clinical stage that have not yet generated significant sales, reflecting that costs are not yet offset by revenue. The company holds $276.08M in cash against $47.14M in debt, resulting in a Debt to Equity ratio of 14.50, which suggests a highly leveraged balance sheet relative to equity, though the absolute debt level is manageable given the cash position. The Current Ratio is 10.04, indicating exceptionally strong short-term liquidity where current assets far exceed current liabilities, providing a robust buffer against immediate financial obligations. Return on Equity is -33.3% and Return on Assets is -18.3%, metrics that reveal that management is currently destroying shareholder value on a percentage basis due to the lack of profitable operations, a standard characteristic for pre-commercialization biotech firms.
मूल्यांकन आकलन
The Trailing P/E Ratio is N/A and the Forward P/E is -32.06, a disparity that implies the market is pricing the stock based on future earnings expectations that are currently negative, meaning traditional profitability-based valuation models are not applicable at this stage. The Price to Book ratio is 15.17, indicating a significant market premium over the company's book value, which reflects high expectations for the successful commercialization of its therapeutic pipeline despite current losses. The Price to Sales ratio is N/A and the EV/EBITDA is -40.27, suggesting that alternative valuation metrics also highlight the speculative nature of the investment as earnings and sales figures are insufficient to support a positive multiple. The 52-Week High is $18.20 and the 52-Week Low is $1.01; without a specific current price listed in the facts, the valuation context remains defined by this wide range, but the high EV/EBITDA of -40.27 underscores the extreme valuation risk associated with negative earnings. The Beta is 1.05, which indicates that the stock's price volatility is slightly higher than the broader market, meaning it will tend to move with a slight degree of amplified intensity relative to general market fluctuations.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, preventing a direct comparison of growth rates but confirming that the company is not yet in a mature expansion phase where revenue scales predictably. As the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that the firm retains all its limited earnings and cash reserves to reinvest into research and development rather than distributing income to shareholders. This reinvestment strategy is essential for a clinical-stage company that must fund expensive clinical trials and regulatory submissions to bring its therapies to market before it can ever consider paying dividends. The overall growth and income profile is characterized by zero current profitability and zero dividend yield, with the company's value entirely dependent on the successful execution of its clinical pipeline and the eventual generation of sales from its oncology treatments.